HIF1A and head and neck cancer: A crucial aspect is its ability to suppress HIF-1α activation under hypoxic conditions [11], suggesting its potential as an adjuvant in chemotherapy, sensitizing head and neck cancer cells to gefitinib [39] and suppressing angiogenesis [40].